Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 201–210 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 201
- Medicine slug
- brinzolamide
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 6
- Source count
- 6
- Agreement rate
- 1
- Recorded readings
111 days
- Numeric value
- Not parsed
- Unit
- Not recorded
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37b19837-fcab-4536-abad-6f4f92dfe794 (opens source in a new tab)
Brinzolamide label
Version not recorded · Effective date not recorded
Due to its affinity for carbonic anhydrase II, brinzolamide distributes extensively into the RBCs and exhibits a long half-life in whole blood (approximately 111 days).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0afb6589-51ba-432c-aed1-20a12d5d3455 (opens source in a new tab)
Brinzolamide label
Version not recorded · Effective date not recorded
Due to its affinity for carbonic anhydrase II, brinzolamide distributes extensively into the RBCs and exhibits a long half-life in whole blood (approximately 111 days).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed6dbc25-47d7-42db-9787-5814d71f45ce (opens source in a new tab)
Brinzolamide label
Version not recorded · Effective date not recorded
Due to its affinity for carbonic anhydrase II, brinzolamide distributes extensively into the RBCs and exhibits a long half-life in whole blood (approximately 111 days).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b56a2e4b-7502-4831-a5b1-0370bdb987b1 (opens source in a new tab)
Brinzolamide label
Version not recorded · Effective date not recorded
Due to its affinity for carbonic anhydrase II, brinzolamide distributes extensively into the RBCs and exhibits a long half-life in whole blood (approximately 111 days).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:460baf5f-1d47-4ae0-b635-84507c3b028d (opens source in a new tab)
Brinzolamide label
Version not recorded · Effective date not recorded
Due to its affinity for carbonic anhydrase II, brinzolamide distributes extensively into the RBCs and exhibits a long half-life in whole blood (approximately 111 days).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fb7229d4-522e-4cb2-b513-9d34f3ded591 (opens source in a new tab)
Brinzolamide label
Version not recorded · Effective date not recorded
Due to its affinity for carbonic anhydrase II, brinzolamide distributes extensively into the RBCs and exhibits a long half-life in whole blood (approximately 111 days).
Projected row 202
- Medicine slug
- brivaracetam
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 21
- Source count
- 21
- Agreement rate
- 1
- Recorded readings
9 hours
- Numeric value
- 9
- Unit
- hours
- Source records
- 21
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 21 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41e218af-048b-4e24-91d2-0b9b262d480c (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The terminal plasma half-life (t 1/2 ) is approximately 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c6af271-3222-4602-98a6-14754f0a29ba (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The terminal plasma half-life (t 1/2 ) is approximately 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57627ea9-3b14-4428-ad95-6ea25ecaef31 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The terminal plasma half-life (t 1/2 ) is approximately 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4ee9b82-1067-4efc-b3d9-f24eb0c461d5 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The terminal plasma half-life (t 1/2 ) is approximately 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1915620d-4f37-56c2-437e-8362bb462d07 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The terminal plasma half-life (t 1/2 ) is approximately 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dca92c5b-78a8-4ee1-9f06-18320ae2a2e8 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The terminal plasma half-life (t 1/2 ) is approximately 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c054a1c9-2aa7-473b-a04b-622596f36c95 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The terminal plasma half-life (t 1/2 ) is approximately 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49f726ec-e51b-7516-e063-6294a90ae684 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The terminal plasma half-life (t 1/2 ) is approximately 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11ca0e1d-1c0d-4357-9ebd-ee1e87185dde (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The terminal plasma half-life (t 1/2 ) is approximately 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ea51292-fe03-46f5-9d9b-36986f5b7224 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The terminal plasma half-life (t 1/2 ) is approximately 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5115c5b4-7a23-89f2-e063-6294a90a222a (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The terminal plasma half-life (t 1/2 ) is approximately 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57cfb2c3-395d-0892-e063-6294a90a1064 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The terminal plasma half-life (t 1/2 ) is approximately 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aef3ee92-e2a6-4135-94b2-b893f893d5f2 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The terminal plasma half-life (t 1/2 ) is approximately 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bdbb6756-654c-46f1-a85c-7d5d1a89685a (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The terminal plasma half-life (t 1/2 ) is approximately 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d54ca946-2ddf-4a67-87c9-20a814bfd2dc (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The terminal plasma half-life (t 1/2 ) is approximately 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf372f42-cfc9-4fcf-8226-3936ba8833d7 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The terminal plasma half-life (t 1/2 ) is approximately 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5bc0f4c0-8b31-4622-849f-d902be93788b (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The terminal plasma half-life (t 1/2 ) is approximately 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59817617-956e-4685-81d4-7abe42f4de86 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The terminal plasma half-life (t 1/2 ) is approximately 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7957cc22-2e0f-489d-9fa1-99520f615934 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The terminal plasma half-life (t1/2) is approximately 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:260468dd-a604-488a-a47b-b6d82edcca37 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The terminal plasma half-life (t 1/2 ) is approximately 9 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3cf2f439-0e97-443e-8e33-25ecef616f6c (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The terminal plasma half-life (t 1/2 ) is approximately 9 hours.
Projected row 203
- Medicine slug
- brivaracetam
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 21
- Source count
- 21
- Agreement rate
- 1
- Recorded readings
20%
- Numeric value
- 20
- Unit
- %
- Source records
- 21
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 21 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41e218af-048b-4e24-91d2-0b9b262d480c (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
Distribution Brivaracetam is weakly bound to plasma proteins (≤20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c6af271-3222-4602-98a6-14754f0a29ba (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
Distribution Brivaracetam is weakly bound to plasma proteins (≤20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57627ea9-3b14-4428-ad95-6ea25ecaef31 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
Distribution Brivaracetam is weakly bound to plasma proteins (≤20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4ee9b82-1067-4efc-b3d9-f24eb0c461d5 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
Distribution Brivaracetam is weakly bound to plasma proteins (≤20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1915620d-4f37-56c2-437e-8362bb462d07 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
Distribution Brivaracetam is weakly bound to plasma proteins (≤20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dca92c5b-78a8-4ee1-9f06-18320ae2a2e8 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
Distribution Brivaracetam is weakly bound to plasma proteins (≤20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c054a1c9-2aa7-473b-a04b-622596f36c95 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
Distribution Brivaracetam is weakly bound to plasma proteins (≤20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49f726ec-e51b-7516-e063-6294a90ae684 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
Distribution Brivaracetam is weakly bound to plasma proteins (≤ 20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11ca0e1d-1c0d-4357-9ebd-ee1e87185dde (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
Distribution Brivaracetam is weakly bound to plasma proteins (≤20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ea51292-fe03-46f5-9d9b-36986f5b7224 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
Distribution Brivaracetam is weakly bound to plasma proteins (≤20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5115c5b4-7a23-89f2-e063-6294a90a222a (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
Distribution Brivaracetam is weakly bound to plasma proteins (≤20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57cfb2c3-395d-0892-e063-6294a90a1064 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
Distribution Brivaracetam is weakly bound to plasma proteins (≤20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aef3ee92-e2a6-4135-94b2-b893f893d5f2 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
Distribution Brivaracetam is weakly bound to plasma proteins (≤20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bdbb6756-654c-46f1-a85c-7d5d1a89685a (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
Distribution Brivaracetam is weakly bound to plasma proteins (≤20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d54ca946-2ddf-4a67-87c9-20a814bfd2dc (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
Distribution Brivaracetam is weakly bound to plasma proteins (≤ 20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf372f42-cfc9-4fcf-8226-3936ba8833d7 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
Distribution Brivaracetam is weakly bound to plasma proteins (≤20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5bc0f4c0-8b31-4622-849f-d902be93788b (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
Distribution Brivaracetam is weakly bound to plasma proteins (≤20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59817617-956e-4685-81d4-7abe42f4de86 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
Distribution Brivaracetam is weakly bound to plasma proteins (≤20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7957cc22-2e0f-489d-9fa1-99520f615934 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
Distribution Brivaracetam is weakly bound to plasma proteins (≤20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:260468dd-a604-488a-a47b-b6d82edcca37 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
Distribution Brivaracetam is weakly bound to plasma proteins (≤20%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3cf2f439-0e97-443e-8e33-25ecef616f6c (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
Distribution Brivaracetam is weakly bound to plasma proteins (≤20%).
Projected row 204
- Medicine slug
- brivaracetam
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 21
- Source count
- 21
- Agreement rate
- 1
- Recorded readings
1 hour
- Numeric value
- 1
- Unit
- hours
- Source records
- 21
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 21 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41e218af-048b-4e24-91d2-0b9b262d480c (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The median T max for tablets taken without food is 1 hour (range 0.25 to 3 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c6af271-3222-4602-98a6-14754f0a29ba (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The median T max for tablets taken without food is 1 hour (range 0.25 to 3 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57627ea9-3b14-4428-ad95-6ea25ecaef31 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The median T max for tablets taken without food is 1 hour (range 0.25 to 3 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4ee9b82-1067-4efc-b3d9-f24eb0c461d5 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The median T max for tablets taken without food is 1 hour (range 0.25 to 3 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1915620d-4f37-56c2-437e-8362bb462d07 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The median T max for tablets taken without food is 1 hour (range 0.25 to 3 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dca92c5b-78a8-4ee1-9f06-18320ae2a2e8 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The median T max for tablets taken without food is 1 hour (range 0.25 to 3 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c054a1c9-2aa7-473b-a04b-622596f36c95 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The median T max for tablets taken without food is 1 hour (range 0.25 to 3 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49f726ec-e51b-7516-e063-6294a90ae684 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The median T max for tablets taken without food is 1 hour (range 0.25 to 3 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11ca0e1d-1c0d-4357-9ebd-ee1e87185dde (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The median T max for tablets taken without food is 1 hour (range 0.25 to 3 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ea51292-fe03-46f5-9d9b-36986f5b7224 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The median T max for tablets taken without food is 1 hour (range 0.25 to 3 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5115c5b4-7a23-89f2-e063-6294a90a222a (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The median T max for tablets taken without food is 1 hour (range 0.25 to 3 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57cfb2c3-395d-0892-e063-6294a90a1064 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The median T max for tablets taken without food is 1 hour (range 0.25 to 3 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aef3ee92-e2a6-4135-94b2-b893f893d5f2 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The median T max for tablets taken without food is 1 hour (range 0.25 to 3 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bdbb6756-654c-46f1-a85c-7d5d1a89685a (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The median T max for tablets taken without food is 1 hour (range 0.25 to 3 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d54ca946-2ddf-4a67-87c9-20a814bfd2dc (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The median T max for tablets taken without food is 1 hour (range 0.25 hour to 3 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf372f42-cfc9-4fcf-8226-3936ba8833d7 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The median T max for tablets taken without food is 1 hour (range 0.25 to 3 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5bc0f4c0-8b31-4622-849f-d902be93788b (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The median T max for tablets taken without food is 1 hour (range 0.25 to 3 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59817617-956e-4685-81d4-7abe42f4de86 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The median T max for tablets taken without food is 1 hour (range 0.25 to 3 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7957cc22-2e0f-489d-9fa1-99520f615934 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The median T max for tablets taken without food is 1 hour (range 0.25 to 3 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:260468dd-a604-488a-a47b-b6d82edcca37 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The median T max for tablets taken without food is 1 hour (range 0.25 to 3 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3cf2f439-0e97-443e-8e33-25ecef616f6c (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The median T max for tablets taken without food is 1 hour (range 0.25 to 3 hours).
Projected row 205
- Medicine slug
- brivaracetam
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 21
- Source count
- 21
- Agreement rate
- 1
- Recorded readings
0.5 L/kg
- Numeric value
- 0.5
- Unit
- L/kg
- Source records
- 21
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 21 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41e218af-048b-4e24-91d2-0b9b262d480c (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The volume of distribution is 0.5 L/kg, a value close to that of the total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c6af271-3222-4602-98a6-14754f0a29ba (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The volume of distribution is 0.5 L/kg, a value close to that of the total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57627ea9-3b14-4428-ad95-6ea25ecaef31 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The volume of distribution is 0.5 L/kg, a value close to that of the total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4ee9b82-1067-4efc-b3d9-f24eb0c461d5 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The volume of distribution is 0.5 L/kg, a value close to that of the total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1915620d-4f37-56c2-437e-8362bb462d07 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The volume of distribution is 0.5 L/kg, a value close to that of the total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dca92c5b-78a8-4ee1-9f06-18320ae2a2e8 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The volume of distribution is 0.5 L/kg, a value close to that of the total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c054a1c9-2aa7-473b-a04b-622596f36c95 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The volume of distribution is 0.5 L/kg, a value close to that of the total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49f726ec-e51b-7516-e063-6294a90ae684 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The volume of distribution is 0.5 L/kg, a value close to that of the total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11ca0e1d-1c0d-4357-9ebd-ee1e87185dde (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The volume of distribution is 0.5 L/kg, a value close to that of the total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ea51292-fe03-46f5-9d9b-36986f5b7224 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The volume of distribution is 0.5 L/kg, a value close to that of the total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5115c5b4-7a23-89f2-e063-6294a90a222a (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The volume of distribution is 0.5 L/kg, a value close to that of the total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57cfb2c3-395d-0892-e063-6294a90a1064 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The volume of distribution is 0.5 L/kg, a value close to that of the total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aef3ee92-e2a6-4135-94b2-b893f893d5f2 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The volume of distribution is 0.5 L/kg, a value close to that of the total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bdbb6756-654c-46f1-a85c-7d5d1a89685a (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The volume of distribution is 0.5 L/kg, a value close to that of the total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d54ca946-2ddf-4a67-87c9-20a814bfd2dc (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The volume of distribution is 0.5 L/kg, a value close to that of the total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf372f42-cfc9-4fcf-8226-3936ba8833d7 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The volume of distribution is 0.5 L/kg, a value close to that of the total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5bc0f4c0-8b31-4622-849f-d902be93788b (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The volume of distribution is 0.5 L/kg, a value close to that of the total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59817617-956e-4685-81d4-7abe42f4de86 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The volume of distribution is 0.5 L/kg, a value close to that of the total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7957cc22-2e0f-489d-9fa1-99520f615934 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The volume of distribution is 0.5 L/kg, a value close to that of the total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:260468dd-a604-488a-a47b-b6d82edcca37 (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The volume of distribution is 0.5 L/kg, a value close to that of the total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3cf2f439-0e97-443e-8e33-25ecef616f6c (opens source in a new tab)
Brivaracetam label
Version not recorded · Effective date not recorded
The volume of distribution is 0.5 L/kg, a value close to that of the total body water.
Projected row 206
- Medicine slug
- bromocriptine
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 8
- Source count
- 8
- Agreement rate
- 0.875
- Recorded readings
2.5 hrs
- Numeric value
- 2.5
- Unit
- hours
- Source records
- 7
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 7 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29827cb6-f8fe-424f-80ef-48f4ef460122 (opens source in a new tab)
Bromocriptine label
Version not recorded · Effective date not recorded
esylate tablets, 2 x 2.5 mg to 5 healthy volunteers under fasted conditions, the mean peak plasma levels of bromocriptine, time to reach peak plasma concentrations and elimination half-life were 465 pg/mL ± 226, 2.5 hrs ± 2 and 4.85 hr, respectively. 1 Linear relationship was found between single doses of bromocriptine mesylate and C max and AUC in the dose range of 1 to 7.5 mg. 2 The pharmacokine
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d69003ee-0b6f-47a9-834e-ba59c02f566c (opens source in a new tab)
Bromocriptine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following single 5 mg bromocriptine mesylate capsules dose (two 2.5 mg tablets) to five healthy volunteers under fasted conditions, the mean peak bromocriptine plasma levels, time to reach peak bromocriptine plasma concentrations and elimination half-life were 465 pg/mL ± 226, 2.5 hours ± 2 and 4.9 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:72d8eefe-c066-41b6-8922-9586f1cf47a1 (opens source in a new tab)
Bromocriptine label
Version not recorded · Effective date not recorded
esylate tablets, 2 x 2.5 mg to 5 healthy volunteers under fasted conditions, the mean peak plasma levels of bromocriptine, time to reach peak plasma concentrations and elimination half-life were 465 pg/mL ± 226, 2.5 hrs ± 2 and 4.85 hr, respectively. 1 Linear relationship was found between single doses of bromocriptine and C max and AUC in the dose range of 1 to 7.5 mg. 2 The pharmacokinetics of b
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ddd292a5-72af-448f-8b88-cc4fd99ec783 (opens source in a new tab)
Bromocriptine label
Version not recorded · Effective date not recorded
esylate tablets, 2 x 2.5 mg to 5 healthy volunteers under fasted conditions, the mean peak plasma levels of bromocriptine, time to reach peak plasma concentrations and elimination half-life were 465 pg/mL ± 226, 2.5 hrs ± 2 and 4.85 hr, respectively. 1 Linear relationship was found between single doses of bromocriptine mesylate and C max and AUC in the dose range of 1 to 7.5 mg. 2 The pharmacokine
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ee2da00-faf8-4c51-a696-9462fa4f6050 (opens source in a new tab)
Bromocriptine label
Version not recorded · Effective date not recorded
esylate tablets, 2 x 2.5 mg to 5 healthy volunteers under fasted conditions, the mean peak plasma levels of bromocriptine, time to reach peak plasma concentrations and elimination half-life were 465 pg/mL ± 226, 2.5 hrs ± 2 and 4.85 hr, respectively. 1 Linear relationship was found between single doses of bromocriptine mesylate and C max and AUC in the dose range of 1 to 7.5 mg. 2 The pharmacokine
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:17f3a343-1782-4799-95ba-31dfe93be2cf (opens source in a new tab)
Bromocriptine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following single 5 mg bromocriptine mesylate dose (two 2.5 mg tablets) to five healthy volunteers under fasted conditions, the mean peak bromocriptine plasma levels, time to reach peak bromocriptine plasma concentrations and elimination half-life were 465 pg/mL ± 226, 2.5 hours ± 2 and 4.9 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c43c300d-8aec-4020-984a-42c1a917c08f (opens source in a new tab)
Bromocriptine label
Version not recorded · Effective date not recorded
esylate tablets, 2 x 2.5 mg to 5 healthy volunteers under fasted conditions, the mean peak plasma levels of bromocriptine, time to reach peak plasma concentrations and elimination half-life were 465 pg/mL ± 226, 2.5 hrs ± 2 and 4.85 hr, respectively. 1 Linear relationship was found between single doses of bromocriptine mesylate and C max and AUC in the dose range of 1 to 7.5 mg. 2 The pharmacokine
6 hours
- Numeric value
- 6
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e42ba916-16b9-4d1c-8d09-9d2fbb1b6c20 (opens source in a new tab)
Bromocriptine label
Version not recorded · Effective date not recorded
The elimination half-life is approximately 6 hours.
Projected row 207
- Medicine slug
- budesonide
- Compared field
- bioavailability
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 51
- Source count
- 12
- Agreement rate
- 0.916667
- Recorded readings
9%
- Numeric value
- 9
- Unit
- %
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a8e79df-3946-4e9a-b214-e9fdd824b565 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Mean oral bioavailability of budesonide ranged from 9% to 21% both in patients and in healthy subjects, demonstrating a high first-pass elimination of the drug.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33def4dc-b469-f987-e063-6294a90ace0b (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Mean oral bioavailability of budesonide ranged from 9% to 21% both in patients and in healthy subjects, demonstrating a high first-pass elimination of the drug.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:263303c2-8e4f-7b6c-e063-6394a90aef9e (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Mean oral bioavailability of budesonide ranged from 9% to 21% both in patients and in healthy subjects, demonstrating a high first-pass elimination of the drug.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4943ef5b-f48b-49d6-b419-467f71ef64e0 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Mean oral bioavailability of budesonide ranged from 9% to 21% both in patients and in healthy subjects, demonstrating a high first-pass elimination of the drug.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b15102d5-7884-44ed-8340-046d7b516fa8 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Mean oral bioavailability of budesonide ranged from 9% to 21% both in patients and in healthy subjects, demonstrating a high first-pass elimination of the drug.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a37866df-df07-4f71-8591-98c2804c4794 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Mean oral bioavailability of budesonide ranged from 9% to 21% both in patients and in healthy subjects, demonstrating a high first-pass elimination of the drug.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10336e42-0e9d-45c4-80bc-5149d5ec9e1c (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Mean oral bioavailability of budesonide ranged from 9% to 21% both in patients and in healthy subjects, demonstrating a high first-pass elimination of the drug.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a18d5a7-04c5-4137-8155-70a8adc0a48b (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Mean oral bioavailability of budesonide ranged from 9% to 21% both in patients and in healthy subjects, demonstrating a high first-pass elimination of the drug.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7aca8d1-159e-4aac-b92d-3a69a8edceec (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Mean oral bioavailability of budesonide ranged from 9% to 21% both in patients and in healthy subjects, demonstrating a high first-pass elimination of the drug.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29863154-5f98-410e-9bf3-0f08b551edef (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Mean oral bioavailability of budesonide ranged from 9% to 21% both in patients and in healthy subjects, demonstrating a high first-pass elimination of the drug.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e39c491-2793-410e-b77f-8b3cbe9b6231 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Mean oral bioavailability of budesonide ranged from 9% to 21% both in patients and in healthy subjects, demonstrating a high first-pass elimination of the drug.
14%
- Numeric value
- 14
- Unit
- %
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56f2023a-69b2-4470-b4ad-af7ec1be527a (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
The oral bioavailability of budesonide in healthy subjects is estimated to be 14% under fasting state.
Projected row 208
- Medicine slug
- budesonide
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 51
- Source count
- 38
- Agreement rate
- 0.526316
- Recorded readings
2.3 hours
- Numeric value
- 2.3
- Unit
- hours
- Source records
- 20
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 20 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2414058b-5d39-42f2-915f-03a5e1101ab5 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
In asthmatic children 4 to 6 years of age, the terminal half-life of budesonide after nebulization is 2.3 hours, and the systemic clearance is 0.5 L/min, which is approximately 50% greater than in healthy adults after adjustment for differences in weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e8a6cf4-4bda-4e22-8653-12635adfb316 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
In asthmatic children 4 to 6 years of age, the terminal half-life of budesonide after nebulization is 2.3 hours, and the systemic clearance is 0.5 L/min, which is approximately 50% greater than in healthy adults after adjustment for differences in weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7df2a10-4166-423e-bb60-5f3a8234f26c (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
In asthmatic children 4 to 6 years of age, the terminal half-life of budesonide after nebulization is 2.3 hours, and the systemic clearance is 0.5 L/min, which is approximately 50% greater than in healthy adults after adjustment for differences in weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8ef9489-83a2-4817-b21c-ea3fecd8c8dd (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
In asthmatic children 4 to 6 years of age, the terminal half-life of budesonide after nebulization is 2.3 hours, and the systemic clearance is 0.5 L/min, which is approximately 50% greater than in healthy adults after adjustment for differences in weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32e30f11-e19b-4e23-a893-92d95e48edef (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
In asthmatic children 4 to 6 years of age, the terminal half-life of budesonide after nebulization is 2.3 hours, and the systemic clearance is 0.5 L/min, which is approximately 50% greater than in healthy adults after adjustment for differences in weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a7d97e0-36f7-4ac9-8f9b-4c3aac568c2b (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
In asthmatic children 4 to 6 years of age, the terminal half-life of budesonide after nebulization is 2.3 hours, and the systemic clearance is 0.5 L/min, which is approximately 50% greater than in healthy adults after adjustment for differences in weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:521a79d0-4d93-45f7-8feb-8d2b502dd216 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
In asthmatic children 4 to 6 years of age, the terminal half-life of budesonide after nebulization is 2.3 hours, and the systemic clearance is 0.5 L/min, which is approximately 50% greater than in healthy adults after adjustment for differences in weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c70c734f-2431-4414-bb94-4adda4985e5d (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
In asthmatic children 4 to 6 years of age, the terminal half-life of budesonide after nebulization is 2.3 hours, and the systemic clearance is 0.5 L/min, which is approximately 50% greater than in healthy adults after adjustment for differences in weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d139a25-9c17-4b3e-8ffd-b2d562cc00ee (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
In asthmatic children 4 to 6 years of age, the terminal half-life of budesonide after nebulization is 2.3 hours, and the systemic clearance is 0.5 L/min, which is approximately 50% greater than in healthy adults after adjustment for differences in weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c52c5382-1400-44b9-95be-a30e1cf706da (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
In asthmatic children 4-6 years of age, the terminal half-life of budesonide after nebulization is 2.3 hours, and the systemic clearance is 0.5 L/min, which is approximately 50% greater than in healthy adults after adjustment for differences in weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:374013c9-18c9-4419-b9fb-9bc5c765688e (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
In asthmatic children 4 to 6 years of age, the terminal half-life of budesonide after nebulization is 2.3 hours, and the systemic clearance is 0.5 L/min, which is approximately 50% greater than in healthy adults after adjustment for differences in weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f126a29-38f7-4c4c-8978-37e72b289902 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
In asthmatic children 4 to 6 years of age, the terminal half-life of budesonide after nebulization is 2.3 hours, and the systemic clearance is 0.5 L/min, which is approximately 50% greater than in healthy adults after adjustment for differences in weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f12043df-f9a3-4edb-88f8-dd176c1a141c (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
In asthmatic children 4 to 6 years of age, the terminal half-life of budesonide after nebulization is 2.3 hours, and the systemic clearance is 0.5 L/min, which is approximately 50% greater than in healthy adults after adjustment for differences in weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a39fbcfc-3ffd-44bd-b882-01f8e1844213 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
In asthmatic children 4 to 6 years of age, the terminal half-life of budesonide after nebulization is 2.3 hours, and the systemic clearance is 0.5 L/min, which is approximately 50% greater than in healthy adults after adjustment for differences in weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d406759d-4c02-4fc0-b513-56b303afca98 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
In asthmatic children 4 to 6 years of age, the terminal half-life of budesonide after nebulization is 2.3 hours, and the systemic clearance is 0.5 L/min, which is approximately 50% greater than in healthy adults after adjustment for differences in weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d90ffda1-12c7-4726-90e9-64bb103e84b5 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
In asthmatic children 4 to 6 years of age, the terminal half-life of budesonide after nebulization is 2.3 hours, and the systemic clearance is 0.5 L/min, which is approximately 50% greater than in healthy adults after adjustment for differences in weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dcb35488-23c5-4e7b-ab86-8406cf855748 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
In asthmatic children 4-6 years of age, the terminal half-life of budesonide after nebulization is 2.3 hours, and the systemic clearance is 0.5 L/min, which is approximately 50% greater than in healthy adults after adjustment for differences in weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9656442-4587-4867-9a8c-5f5b0402936e (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
In asthmatic children 4-6 years of age, the terminal half-life of budesonide after nebulization is 2.3 hours, and the systemic clearance is 0.5 L/min, which is approximately 50% greater than in healthy adults after adjustment for differences in weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33cd9834-76df-4f26-3fa2-aab6b9eee8f2 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
In asthmatic children 4-6 years of age, the terminal half-life of budesonide after nebulization is 2.3 hours, and the systemic clearance is 0.5 L/min, which is approximately 50% greater than in healthy adults after adjustment for differences in weight.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3235e2a4-8e12-2d58-e063-6294a90a4936 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
In asthmatic children 4 to 6 years of age, the terminal half-life of budesonide after nebulization is 2.3 hours, and the systemic clearance is 0.5 L/min, which is approximately 50% greater than in healthy adults after adjustment for differences in weight.
1.9 hours
- Numeric value
- 1.9
- Unit
- hours
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a8e79df-3946-4e9a-b214-e9fdd824b565 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
The mean elimination half-life was 1.9 hours in pediatric patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33def4dc-b469-f987-e063-6294a90ace0b (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
The mean elimination half-life was 1.9 hours in pediatric patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:263303c2-8e4f-7b6c-e063-6394a90aef9e (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
The mean elimination half-life was 1.9 hours in pediatric patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4943ef5b-f48b-49d6-b419-467f71ef64e0 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
The mean elimination half-life was 1.9 hours in pediatric patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b15102d5-7884-44ed-8340-046d7b516fa8 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
The mean elimination half-life was 1.9 hours in pediatric patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a37866df-df07-4f71-8591-98c2804c4794 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
The mean elimination half-life was 1.9 hours in pediatric patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10336e42-0e9d-45c4-80bc-5149d5ec9e1c (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
The mean elimination half-life was 1.9 hours in pediatric patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a18d5a7-04c5-4137-8155-70a8adc0a48b (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
The mean elimination half-life was 1.9 hours in pediatric patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7aca8d1-159e-4aac-b92d-3a69a8edceec (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
The mean elimination half-life was 1.9 hours in pediatric patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29863154-5f98-410e-9bf3-0f08b551edef (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
The mean elimination half-life was 1.9 hours in pediatric patients.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e39c491-2793-410e-b77f-8b3cbe9b6231 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
The mean elimination half-life was 1.9 hours in pediatric patients.
2 to 3 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10ea5d87-6ed0-4fa5-a37b-2043c8560bc0 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
The terminal half-life, 2 to 3 hours, was the same for both epimers and was independent of dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae1105cd-69fc-4c15-937f-c535304341c2 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
The terminal half-life, 2 to 3 hours, was the same for both epimers and was independent of dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79fc8cf4-bb33-4892-9dd2-641d7e943a01 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
The terminal half-life, 2 to 3 hours, was the same for both epimers and was independent of dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10f2ae5b-a6fb-4804-9111-0cd067c2b1b2 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
The terminal half-life, 2 to 3 hours, was the same for both epimers and was independent of dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d0c6c7e-2f53-4238-ab34-bd8cf49d8a66 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
The terminal half-life, 2 to 3 hours, was the same for both epimers and was independent of dose.
3.3 hours
- Numeric value
- 3.3
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56f2023a-69b2-4470-b4ad-af7ec1be527a (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
The mean plasma elimination half-life (t 1/2 ) of budesonide after administration of EOHILIA was 3.3 hours.
5.0 to 6.8 hours
- Numeric value
- 5
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:938cada4-d6bf-4252-836f-dd40f9eadb4d (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Following single oral administration of TARPEYO 16 mg to healthy subjects, the elimination half-life (t½) for TARPEYO ranged from 5.0 to 6.8 hours.
Projected row 209
- Medicine slug
- budesonide
- Compared field
- proteinBinding
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 51
- Source count
- 19
- Agreement rate
- 0.631579
- Recorded readings
85%
- Numeric value
- 85
- Unit
- %
- Source records
- 12
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 12 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a8e79df-3946-4e9a-b214-e9fdd824b565 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Plasma protein binding was estimated to be 85% to 90% in the concentration range 0.43 to 99.02 ng/mL, independent of gender.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33def4dc-b469-f987-e063-6294a90ace0b (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Plasma protein binding was estimated to be 85% to 90% in the concentration range 0.43 to 99.02 ng/mL, independent of gender.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56f2023a-69b2-4470-b4ad-af7ec1be527a (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Plasma protein binding was estimated to be 85% to 90% in the concentration range 0.43 to 99.02 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:263303c2-8e4f-7b6c-e063-6394a90aef9e (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Plasma protein binding was estimated to be 85% to 90% in the concentration range 0.43 to 99.02 ng/mL, independent of gender.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4943ef5b-f48b-49d6-b419-467f71ef64e0 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Plasma protein binding was estimated to be 85% to 90% in the concentration range 0.43 to 99.02 ng/mL, independent of gender.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b15102d5-7884-44ed-8340-046d7b516fa8 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Plasma protein binding was estimated to be 85% to 90% in the concentration range 0.43 to 99.02 ng/mL, independent of gender.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a37866df-df07-4f71-8591-98c2804c4794 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Plasma protein binding was estimated to be 85% to 90% in the concentration range 0.43 to 99.02 ng/mL, independent of gender.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10336e42-0e9d-45c4-80bc-5149d5ec9e1c (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Plasma protein binding was estimated to be 85% to 90% in the concentration range 0.43 ng/mL to 99.02 ng/mL, independent of gender.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a18d5a7-04c5-4137-8155-70a8adc0a48b (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Plasma protein binding was estimated to be 85% to 90% in the concentration range 0.43 to 99.02 ng/mL, independent of gender.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7aca8d1-159e-4aac-b92d-3a69a8edceec (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Plasma protein binding was estimated to be 85% to 90% in the concentration range 0.43 to 99.02 ng/mL, independent of gender.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29863154-5f98-410e-9bf3-0f08b551edef (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Plasma protein binding was estimated to be 85% to 90% in the concentration range 0.43 to 99.02 ng/mL, independent of gender.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e39c491-2793-410e-b77f-8b3cbe9b6231 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Plasma protein binding was estimated to be 85% to 90% in the concentration range 0.43 to 99.02 ng/mL, independent of gender.
85 to 90%
- Numeric value
- 85
- Unit
- %
- Source records
- 7
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 7 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a12b2e99-c8b3-4d08-9af0-8c4a4376ebf1 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 85 to 90% in the concentration range 1 to 230 nmol/L, independent of gender.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad4a68e7-9200-4f05-8058-714d5d8900f8 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 85 to 90% in the concentration range of 1 to 230 nmol/L, independent of gender.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41d4fd39-81ee-41be-b34d-efb12b3a359d (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 85 to 90% in the concentration range 1 to 230 nmol/L, independent of gender.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92cbb190-8851-46ed-bfe0-166ca62ef2e9 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 85 to 90% in the concentration range 1 to 230 nmol/L, independent of gender.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7265276-e649-4bc4-8ac8-1f5ac2b984e8 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 85 to 90% in the concentration range 1 to 230 nmol/L, independent of gender.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b2cf85c5-3ae0-4f91-9f3a-1d6771e14a73 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 85 to 90% in the concentration range of 1 to 230 nmol/L, independent of gender.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:230e4596-2a9b-4d55-b0a0-0cabbcff5289 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Plasma protein binding is estimated to be 85 to 90% in the concentration range of 1 to 230 nmol/L, independent of gender.
Projected row 210
- Medicine slug
- budesonide
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 51
- Source count
- 22
- Agreement rate
- 0.5
- Recorded readings
3.5 hours
- Numeric value
- 3.5
- Unit
- hours
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a8e79df-3946-4e9a-b214-e9fdd824b565 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
The time to peak concentration (T max ) varied between 2 and 8 hours with a median value of 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33def4dc-b469-f987-e063-6294a90ace0b (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
The time to peak concentration (T max ) varied between 2 and 8 hours with a median value of 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:263303c2-8e4f-7b6c-e063-6394a90aef9e (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
The time to peak concentration (T max ) varied between 2 and 8 hours with a median value of 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4943ef5b-f48b-49d6-b419-467f71ef64e0 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
The time to peak concentration (T max ) varied between 2 and 8 hours with a median value of 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b15102d5-7884-44ed-8340-046d7b516fa8 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
The time to peak concentration (T max ) varied between 2 and 8 hours with a median value of 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a37866df-df07-4f71-8591-98c2804c4794 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
The time to peak concentration (T max ) varied between 2 and 8 hours with a median value of 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10336e42-0e9d-45c4-80bc-5149d5ec9e1c (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
The time to peak concentration (T max ) varied between 2 and 8 hours with a median value of 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a18d5a7-04c5-4137-8155-70a8adc0a48b (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
The time to peak concentration (T max ) varied between 2 and 8 hours with a median value of 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7aca8d1-159e-4aac-b92d-3a69a8edceec (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
The time to peak concentration (T max ) varied between 2 and 8 hours with a median value of 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29863154-5f98-410e-9bf3-0f08b551edef (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
The time to peak concentration (T max ) varied between 2 and 8 hours with a median value of 3.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e39c491-2793-410e-b77f-8b3cbe9b6231 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
The time to peak concentration (T max ) varied between 2 and 8 hours with a median value of 3.5 hours.
1 to 2 hours
- Numeric value
- 1
- Unit
- hours
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10ea5d87-6ed0-4fa5-a37b-2043c8560bc0 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of budesonide, peak plasma concentration was achieved in about 1 to 2 hours and the absolute systemic availability was 6-13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ae1105cd-69fc-4c15-937f-c535304341c2 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of budesonide, peak plasma concentration was achieved in about 1 to 2 hours and the absolute systemic availability was 6-13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79fc8cf4-bb33-4892-9dd2-641d7e943a01 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of budesonide, peak plasma concentration was achieved in about 1 to 2 hours and the absolute systemic availability was 6-13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10f2ae5b-a6fb-4804-9111-0cd067c2b1b2 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of budesonide, peak plasma concentration was achieved in about 1 to 2 hours and the absolute systemic availability was 6-13%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d0c6c7e-2f53-4238-ab34-bd8cf49d8a66 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption After oral administration of budesonide, peak plasma concentration was achieved in about 1 to 2 hours and the absolute systemic availability was 6-13%.
13.3 ± 5.9 hours
- Numeric value
- 13.3
- Unit
- hours
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a12b2e99-c8b3-4d08-9af0-8c4a4376ebf1 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
llowing single oral administration of budesonide extended-release tablets 9 mg in healthy subjects, peak plasma concentration (C max ) was 1.35 ± 0.96 ng/mL, the time to peak concentration (T max ) on average was 13.3 ± 5.9 hours, although it varied across different individual patients, and the area under the plasma concentration time curve (AUC) was approximately 16.43 ± 10.52 ng·hr/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41d4fd39-81ee-41be-b34d-efb12b3a359d (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
llowing single oral administration of budesonide extended-release tablets 9 mg in healthy subjects, peak plasma concentration (C max ) was 1.35 ± 0.96 ng/mL, the time to peak concentration (T max ) on average was 13.3 ± 5.9 hours, although it varied across different individual patients, and the area under the plasma concentration time curve (AUC) was approximately 16.43 ± 10.52 ng·hr/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92cbb190-8851-46ed-bfe0-166ca62ef2e9 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following single oral administration of UCERIS 9 mg in healthy subjects, peak plasma concentration (C max ) was 1.35 ± 0.96 ng/mL, the time to peak concentration (T max ) on average was 13.3 ± 5.9 hours, although it varied across different individual patients, and the area under the plasma concentration time curve (AUC) was approximately 16.43 ± 10.52 ng·hr/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7265276-e649-4bc4-8ac8-1f5ac2b984e8 (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
llowing single oral administration of budesonide extended-release tablets 9 mg in healthy subjects, peak plasma concentration (C max ) was 1.35 ± 0.96 ng/mL, the time to peak concentration (T max ) on average was 13.3 ± 5.9 hours, although it varied across different individual patients, and the area under the plasma concentration time curve (AUC) was approximately 16.43 ± 10.52 ng•hr/mL.
2 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56f2023a-69b2-4470-b4ad-af7ec1be527a (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Absorption The median (range) time to reach budesonide peak plasma concentration (t max ) was 2 hours (range 0.5 to 4 hours) after oral administration of EOHILIA 2 mg twice daily in adult subjects with EoE.
5.1 h
- Numeric value
- 5.1
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:938cada4-d6bf-4252-836f-dd40f9eadb4d (opens source in a new tab)
Budesonide label
Version not recorded · Effective date not recorded
Median T lag (min, max) was 3.1 h (0, 6) while median T max (min, max) was 5.1 h (4.5, 10).
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=200Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.